Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,096 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Vehicle Clear all
Completed Phase 1 Interventional

Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer

NCT00079300
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
imiquimod, conventional surgery
Drug · Procedure
Lead sponsor
National Naval Medical Center
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2013 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

NCT02929823
View directory record Official record
Conditions
Corneal Epithelial Disorders
Interventions
High Dose SJP-0035 Ophthalmic Solution, Low Dose SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic solution
Drug
Lead sponsor
Senju Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
19
States / cities
Little Rock, Arkansas • Glendora, California • Lancaster, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa

NCT03068780
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
Oleogel-S10, Control gel
Drug
Lead sponsor
Amryt Research Limited
Industry
Eligibility
21 Days and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Aurora, Colorado • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 18, 2026, 1:03 AM EDT
Terminated Phase 2Phase 3 Interventional

Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration

NCT01601483
View directory record Official record
Conditions
Nonexudative Age Related Macular Degeneration
Interventions
MC-1101, MC-1101 Vehicle
Drug
Lead sponsor
MacuCLEAR, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Oct 18, 2026, 1:03 AM EDT
Terminated Phase 3 Interventional

A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer

NCT02667327
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Granexin gel, Vehicle gel
Drug · Other
Lead sponsor
Xequel Bio, Inc.
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Los Angeles, California • Doral, Florida • Hialeah, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis

NCT04675242
View directory record Official record
Conditions
Blepharitis
Interventions
NCX 4251, Placebo
Drug
Lead sponsor
Nicox Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)

NCT00366145
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Prochymal®, Placebo, Standard of Care for GVHD
Biological · Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
6 Months to 70 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 18, 2026, 1:03 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects

NCT01602328
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
AC607, Vehicle Only
Biological
Lead sponsor
AlloCure Inc.
Industry
Eligibility
21 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • San Diego, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis

NCT05579899
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
EVO101
Drug
Lead sponsor
Evommune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
21
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris

NCT06733402
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745651
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Fremont, California • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 18, 2026, 1:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Improving Diagnostic Standards in Dysphagia

NCT04773184
View directory record Official record
Conditions
Dysphagia
Interventions
Fiberoptic Endoscopic Evaluation of Swallowing, Videofluoroscopic Swallowing Study, Voluntary Peak Cough Flow Testing, Iowa Oral Performance Instrument, Capsaicin Challenge, Pulmonary Function Testing, Voicing Tasks
Procedure · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

NCT02065375
View directory record Official record
Conditions
Inflammation and Pain Following Ocular Surgery
Interventions
Omaveloxolone Ophthalmic Suspension 1.0%, Omaveloxolone Opthalmic Suspension 0.5%, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Fort Myers, Florida • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

NCT03003247
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-120 Gel, IDP 120 Component A Gel, IDP 120 Component B Gel, IDP 120 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
364 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
20
States / cities
Encino, California • Lake Mary, Florida • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis

NCT01962987
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Diclofenac sodium, Placebo
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
31
States / cities
Fremont, California • Long Beach, California • Newport Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis

NCT02432807
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Vancomycin 1.1%, Placebo
Drug
Lead sponsor
Kurobe LLC
Industry
Eligibility
1 Year and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
16
States / cities
Paramount, California • Petaluma, California • Rancho Cordova, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne

NCT00713609
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Benzoyl peroxide gel, Clindamycin gel, Tazarotene cream, Vehicle gel, Vehicle cream
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years to 45 Years
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
Little Rock, Arkansas • Fremont, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Not applicable Interventional

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

NCT01501799
View directory record Official record
Conditions
Acne Vulgaris
Interventions
adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO, Placebo (Vehicle Gel)
Drug
Lead sponsor
Actavis Mid-Atlantic LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Fremont, California • Miami, Florida • Miramar, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Phase 3 Interventional

Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.

NCT05695781
View directory record Official record
Conditions
Dry Eye Disease
Interventions
BRM421 Ophthalmic Solution, Vehicle
Drug
Lead sponsor
BRIM Biotechnology Inc.
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Warwick, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of RM-493 on Energy Expenditure in Obese Individuals

NCT01867437
View directory record Official record
Conditions
Obesity, Morbid Obesity
Interventions
Placebo, RM-493
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Phase 2 Interventional

DMT210 Topical Gel in the Treatment of Acne Rosacea

NCT03003104
View directory record Official record
Conditions
Acne Rosacea
Interventions
DMT210 Topical Gel 5%, Vehicle Control
Drug · Other
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
9
States / cities
San Diego, California • Miami, Florida • Fridley, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 18, 2026, 1:03 AM EDT
Terminated Phase 4 Interventional Results available

Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer

NCT01459666
View directory record Official record
Conditions
Scar
Interventions
Dysport (abobotulinumtoxinA), Bacteriostatic 0.9% Sodium Chloride (vehicle)
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
2
States / cities
Cleveland, Ohio • Westlake, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Phase 4 Interventional Results available

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

NCT03506477
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis
Interventions
Enstilar® foam, Vehicle foam
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 18, 2026, 1:03 AM EDT
Completed Phase 4 Interventional Results available

CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat

NCT02579096
View directory record Official record
Conditions
Gout, Chronic Kidney Diseases
Interventions
allopurinol capsule, 100-800 mg by mouth once daily, febuxostat tablet 40-120 mg by mouth once daily, Placebo, vehicle control (febuxostat-shaped), Placebo, vehicle control (allopurinol-shaped)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
23
States / cities
Loma Linda, California • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 18, 2026, 1:03 AM EDT